VICXセラピューティクス株式会社

Many academic and research institutes have conducted translational clinical studies where the results have proven safety and efficacy for a variety of investigational therapies; however, these same institutions are slow or incapable of progressing commercial development of these therapeutic products for their practical use in patients. In addition to the potential products awaiting commercial development that are held by academic and research institutes, there are many approved pharmaceutical products overseas that are not yet available in Japan.

VICX therapeutics Co., Ltd. was established on May 29, 2014 as a bio-venture company. We endeavor to accelerate our business aiming to provide advanced medicines and therapies which many patients can trust to use. To achieve our aim we will seek to identify and acquire potential products from academic and research institutes that VICX can rapidly develop and commercialize in Japan; as well as in-license approved pharmaceutical products from foreign sources for marketing in Japan.

Corporate Mission:

Our mission is to develop cutting edge therapeutics by acquiring either potential products that have proven safety and efficacy in translational clinical studies that have been conducted within and outside Japan or approved pharmaceutical products from abroad.

Pipeline:

We aim to obtain sales approval for therapeutic products within a short term of development period by utilizing the Revised Japanese Pharmaceutical Law effectively and introducing promising “seed” products which have qualified safety and efficacy from translational clinical studies.